Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902 (English)
- New search for: Sugawara, S.
- New search for: Oizumi, S.
- New search for: Minato, K.
- New search for: Harada, T.
- New search for: Inoue, A.
- New search for: Fujita, Y.
- New search for: Maemondo, M.
- New search for: Yoshizawa, H.
- New search for: Ito, K.
- New search for: Gemma, A.
- New search for: Sugawara, S.
- New search for: Oizumi, S.
- New search for: Minato, K.
- New search for: Harada, T.
- New search for: Inoue, A.
- New search for: Fujita, Y.
- New search for: Maemondo, M.
- New search for: Yoshizawa, H.
- New search for: Ito, K.
- New search for: Gemma, A.
In:
ANNALS OF ONCOLOGY
;
26
, 5
;
888-894
;
2015
-
ISSN:
- Article (Journal) / Print
-
Title:Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
-
Contributors:Sugawara, S. ( author ) / Oizumi, S. ( author ) / Minato, K. ( author ) / Harada, T. ( author ) / Inoue, A. ( author ) / Fujita, Y. ( author ) / Maemondo, M. ( author ) / Yoshizawa, H. ( author ) / Ito, K. ( author ) / Gemma, A. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 26, 5 ; 888-894
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2015-01-01
-
Size:7 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 26, Issue 5
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 827
-
Adapting the drivers to the road: a new strategy for cancer evolution?Touat, M. / Dhermain, F. / André, F. / Sanson, M. et al. | 2015
- 829
-
An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European research more competitive againDittrich, C. / Negrouk, A. / Casali, P. G. et al. | 2015
- 833
-
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancerOldenburg, J. / Aparicio, J. / Beyer, J. / Cohn-Cedermark, G. / Cullen, M. / Gilligan, T. / De Giorgi, U. / De Santis, M. / de Wit, R. / Fosså, S. D. et al. | 2015
- 838
-
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumorsSerpico, D. / Trama, A. / Haspinger, E. R. / Agustoni, F. / Botta, L. / Berardi, R. / Palmieri, G. / Zucali, P. / Gallucci, R. / Broggini, M. et al. | 2015
- 848
-
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysisLouie, K. S. / Seigneurin, A. / Cathcart, P. / Sasieni, P. et al. | 2015
- 865
-
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Bellera, C. A. / Penel, N. / Ouali, M. / Bonvalot, S. / Casali, P. G. / Nielsen, O. S. / Delannes, M. / Litière, S. / Bonnetain, F. / Dabakuyo, T. S. et al. | 2015
- 873
-
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Gourgou-Bourgade, S. / Cameron, D. / Poortmans, P. / Asselain, B. / Azria, D. / Cardoso, F. / A'Hern, R. / Bliss, J. / Bogaerts, J. / Bonnefoi, H. et al. | 2015
- 880
-
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosomeFavero, F. / McGranahan, N. / Salm, M. / Birkbak, N. J. / Sanborn, J. Z. / Benz, S. C. / Becq, J. / Peden, J. F. / Kingsbury, Z. / Grocok, R. J. et al. | 2015
- 888
-
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Sugawara, S. / Oizumi, S. / Minato, K. / Harada, T. / Inoue, A. / Fujita, Y. / Maemondo, M. / Yoshizawa, H. / Ito, K. / Gemma, A. et al. | 2015
- 894
-
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†Blumenschein, G. R. / Smit, E. F. / Planchard, D. / Kim, D. W. / Cadranel, J. / De Pas, T. / Dunphy, F. / Udud, K. / Ahn, M. J. / Hanna, N. H. et al. | 2015
- 902
-
Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosisJanssen-Heijnen, M. L. / van Erning, F. N. / De Ruysscher, D. K. / Coebergh, J. W. / Groen, H. J. et al. | 2015
- 908
-
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†Pujol, J. L. / Lavole, A. / Quoix, E. / Molinier, O. / Souquet, P. J. / Barlesi, F. / Le Caer, H. / Moro-Sibilot, D. / Fournel, P. / Oster, J. P. et al. | 2015
- 914
-
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†Monk, B. J. / Ghatage, P. / Parekh, T. / Henitz, E. / Knoblauch, R. / Matos-Pita, A. S. / Nieto, A. / Park, Y. C. / Cheng, P. S. / Li, W. et al. | 2015
- 921
-
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†Fuchs, C. S. / Azevedo, S. / Okusaka, T. / Van Laethem, J. L. / Lipton, L. R. / Riess, H. / Szczylik, C. / Moore, M. J. / Peeters, M. / Bodoky, G. et al. | 2015
- 928
-
Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapyvan Gijn, W. / van Stiphout, R. G. / van de Velde, C. J. / Valentini, V. / Lammering, G. / Gambacorta, M. A. / Påhlman, L. / Bujko, K. / Lambin, P. et al. | 2015
- 935
-
The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYCTakahashi, Y. / Sheridan, P. / Niida, A. / Sawada, G. / Uchi, R. / Mizuno, H. / Kurashige, J. / Sugimachi, K. / Sasaki, S. / Shimada, Y. et al. | 2015
- 943
-
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerChen, J. S. / Hsu, C. / Chiang, N. J. / Tsai, C. S. / Tsou, H. H. / Huang, S. F. / Bai, L. Y. / Chang, I. C. / Shiah, H. S. / Ho, C. L. et al. | 2015
- 950
-
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†Renfro, L. A. / Grothey, A. / Kerr, D. / Haller, D. G. / André, T. / Van Cutsem, E. / Saltz, L. / Labianca, R. / Loprinzi, C. L. / Alberts, S. R. et al. | 2015
- 958
-
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaBarta, S. K. / Samuel, M. S. / Xue, X. / Wang, D. / Lee, J. Y. / Mounier, N. / Ribera, J. M. / Spina, M. / Tirelli, U. / Weiss, R. et al. | 2015
- 966
-
Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)Chihara, D. / Asano, N. / Ohmachi, K. / Nishikori, M. / Okamoto, M. / Sawa, M. / Sakai, R. / Okoshi, Y. / Tsukamoto, N. / Yakushijin, Y. et al. | 2015
- 973
-
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200†Chu, Q. S. / Nielsen, T. O. / Alcindor, T. / Gupta, A. / Endo, M. / Goytain, A. / Xu, H. / Verma, S. / Tozer, R. / Knowling, M. et al. | 2015
- 981
-
Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort studyMattsson, T. O. / Holm, B. / Michelsen, H. / Knudsen, J. L. / Brixen, K. / Herrstedt, J. et al. | 2015
- 987
-
Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastasesde Baère, T. / Aupérin, A. / Deschamps, F. / Chevallier, P. / Gaubert, Y. / Boige, V. / Fonck, M. / Escudier, B. / Palussiére, J. et al. | 2015
- 992
-
Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions†van Leeuwen, R. W. / Jansman, F. G. / van den Bemt, P. M. / de Man, F. / Piran, F. / Vincenten, I. / Jager, A. / Rijneveld, A. W. / Brugma, J. D. / Mathijssen, R. H. et al. | 2015
- 998
-
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignanciesWong, A. L. / Soo, R. A. / Tan, D. S. / Lee, S. C. / Lim, J. S. / Marban, P. C. / Kong, L. R. / Lee, Y. J. / Wang, L. Z. / Thuya, W. L. et al. | 2015
- 1005
-
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phaseIsambert, N. / Delord, J. P. / Soria, J. C. / Hollebecque, A. / Gomez-Roca, C. / Purcea, D. / Rouits, E. / Belli, R. / Fumoleau, P. et al. | 2015
- 1012
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationFu, S. / Hou, M. M. / Naing, A. / Janku, F. / Hess, K. / Zinner, R. / Subbiah, V. / Hong, D. / Wheler, J. / Piha-Paul, S. et al. | 2015
- 1019
-
Molecular phenotypes of DCIS predict overall and invasive recurrence†Williams, K. E. / Barnes, N. L. / Cramer, A. / Johnson, R. / Cheema, K. / Morris, J. / Howe, M. / Bundred, N. J. et al. | 2015
- 1025
-
Long-term effects of inhaled budesonide on screening-detected lung nodulesVeronesi, G. / Lazzeroni, M. / Szabo, E. / Brown, P. H. / DeCensi, A. / Guerrieri-Gonzaga, A. / Bellomi, M. / Radice, D. / Grimaldi, M. C. / Spaggiari, L. et al. | 2015
- 1031
-
Letter to the editor concerning ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’Carlsson, S. / Assel, M. / Vickers, A. et al. | 2015
- 1031
-
Reply to the letter to the editor ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’ by Louie et al.Louie, K. S. / Seigneurin, A. / Cathcart, P. / Sasieni, P. et al. | 2015
- 1032
-
Choosing a better end point for trials of bone-protective agentsLeibowitz-Amit, R. / Khoja, L. / Tannock, I. F. / Joshua, A. M. et al. | 2015
- 1033
-
Letter to the editor concerning ‘Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA’Foglietta, J. / Metro, G. / Crinò, L. / Gori, S. et al. | 2015
- 1034
-
How can I validate a nomogram? Show me the modelCollins, G. S. et al. | 2015
- 1035
-
Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancerRossi, G. / Baldi, L. / Barbieri, F. / Bertolini, F. / Tiseo, M. et al. | 2015
- 1036
-
Recent developments in the implementation of novel designs for early-phase combination studiesWages, N. A. / Conaway, M. R. / Slingluff, C. L. / Williams, M. E. / Portell, C. A. / Hwu, P. / Petroni, G. R. et al. | 2015
- 1038
-
A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma| 2015
- 1040
-
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialHebbar, M. / Chibaudel, B. / André, T. / Mineur, L. / Smith, D. / Louvet, C. / Dutel, J. L. / Ychou, M. / Legoux, J. L. / Mabro, M. et al. | 2015